Why the study?
Does RAAS inhibitor discontinuation increase adverse clinical outcomes in patients with an indication for guideline-recommended RAAS inhibitor treatment?
Does RAAS inhibitor discontinuation increase adverse clinical outcomes in patients with an indication for guideline-recommended RAAS inhibitor treatment?
Discontinuation of guideline-recommended RAAS inhibitors is associated with adverse clinical outcomes, highlighting the need to manage factors leading to treatment interruption.
Minimizing RAAS inhibitor interruptions may benefit indicated patients; leaves open causality pending randomized trials.
These findings highlight the need for effective management of factors associated with RAAS inhibitor interruptions or cessations in patients for whom guideline-recommended RAAS inhibitor treatment is indicated.
No takes yet. Share an insight, caveat, or question.
Humphrey et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: